The Company's principal activity is developing gene and cell-based medicines. The Company's product portfolio consists of gene medicines for coronary artery disease, peripheral artery disease and diabetic neuropathy; therapeutic cancer vaccines for breast cancer; recombinant protein medicines for thrombocytopenia, and cell-based gene medicines for chronic granulomatous disease.
Alacra Alerts:
Receive alerts on the latest reports on ViroMed Co Ltd
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
